Francis Xavier Mccormack MD

Interstitial Lung Diseases, Restrictive Lung Disease

Taylor Professor and Director, Division of Pulmonary, Critical Care and Sleep Medicine

Summary

Dr. Francis Mccormack is a pulmonologist in Cincinnati, OH and is affiliated with multiple hospitals in the area, including University of Cincinnati Medical Center, Cincinnati Veterans Affairs Medical Center, Daniel Drake Center for Post Acute Care, and Cincinnati Children's Hospital Medical Center. He received his medical degree from University of Texas Medical Branch and has been in practice 35 years. He specializes in interstitial lung diseases and pleural disease and is experienced in interstitial lung disease, lymphangioleiomyomatosis, critical care medicine, and rare lung diseases.

University of ColoradoFellowship, Pulmonary Disease and Critical Care Medicine, 1986 - 1989
University of MichiganChief Residency, Internal Medicine, 1985 - 1986
University of MichiganResidency, Internal Medicine, 1982 - 1985
University of Texas Medical Branch School of MedicineClass of 1982

PubMed

Pulmonary Manifestations of Lysosomal Storage Disorders in Adults.
Siddhartha Narayanan, Kristen Catherman, Nathan Pajor, Francis X McCormack
Clinics in Chest Medicine. 2025-12-01
Pulmonary Alveolar Microlithiasis: A Disorder of Pulmonary Phosphate Homeostasis.
Christine Y Zhou, Jean M Elwing, Elisabeth Bendstrup, Francis X McCormack
Clinics in Chest Medicine. 2025-12-01
Hydroxyapatite microspheres induce durable pleurodesis and are rapidly cleared by pleural osteoclasts.
Yusuke Tanaka, Yuki Takahashi, Yuma Shindo, Lori B Pitstick, Steven L Teitelbaum
JCI Insight. 2025-10-08

Journal Articles

The Vitamin D Binding Protein Axis Modifies Disease Severity in Lymphangioleiomyomatosis
Francis Mccormack, MD, The European Respiratory Journal
efficacy and safety of sirolimus

Lung and Cardiovascular Development and Disease Pathogenesis Training ProgramNational Heart, Lung and Blood Institute2015–2020
Pathogenesis-Driven Therapeutic Development for Pulmonary Alveolar MicrolithiasisNational Heart, Lung and Blood Institute2015–2019
Molecular Pathway-Driven Diagnostics & Therapeutics for Rare Lung DiseasesNational Heart, Lung and Blood Institute2014–2019
KGF-Modulation of Burn Induced Lung Injury and InfectionShriner’s of North America2013–2018
Therapeutic strategy for Lymphangioleiomyomatosis (LAM) and Tuberous SclerosisNational Heart Lung and Blood Institute2013–2016

Member, FDA Pulmonary and Allergy Drug Advisory Committee 2013 - 2015
Member, American Board of Internal Medicine Pulmonary Board 2013 - 2015
Member, Department of Defense Tuberous Sclerosis Program Vision Setting Committee 2012 - 2015